Moderna Therapeutics has announced the opening of a state-of-the-art manufacturing site in Norwood, Massachusetts, built to advance their work in the messenger RNA (mRNA) platform, after announcing the plans for the site in 2016.
Cure Pharmaceuticals says it plans to apply its drug delivery technologies to Therapix Biosciences’ cannabinoid-based drug pipeline for non-pain indications.
Researchers from Harvard University have developed an insulin formulation using two ionic liquids they say could lead to the development of a pill for diabetics.
Oral tolerability concerns have prompted the US biotech to close Ph II clinical trial investigations of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT).
Sanofi Pasteur has teamed with Translate Bio to develop mRNA vaccines for infectious diseases, using a platform developed by subsidiaries of Shire plc.
SIGA is slated to receive FDA approval for the world’s first antiviral drug to treat smallpox – a milestone not reached in isolation, but in collaboration with several CROs, government agencies, and others.
The Centre for Process Innovation (CPI) has confirmed its role in a UK initiative to accelerate vaccine production and eliminate the need for cold-chain shipping.
Motif Bio plc has secured £10m ($14m) to support the potential commercialization of its lead candidate – iclaprim – which was granted FDA fast-track status in 2015.
A new partnership between Haselmeier and Common Sensing aims to develop smart connected monitoring and support solutions for users of injectable medicines.
Mayne Pharma has opened a new 126,000-square-foot oral solid-dose manufacturing facility to meet demand driven by new product launches – and new revenue stream from its CDMO business.
Pills embedded with sensor technology that verifies a patient has taken their medication can improve adherence and provide data on adverse effects, says Proteus Digital Health’s Nik Leist.
Almac Group has expanded its commercial packaging capabilities to meet a “significant increase” in demand for complex kit assembly as biopharma brings more advanced sterile and biological products to the market, says CDMO.
The US FDA has issued a recall of non-expired products marketed as sterile made by Coastal Meds after an investigation of the outsourcing facility found poor sterile production practices.
Nanoparticle delivery technology that transports compounds to the bloodstream and cells can increase bioavailability and reduce adverse effects of cannabinoids and bioactive compounds, says NanoSphere Health Sciences.
Porton Biopharma will look to develop GMP manufacturing capabilities for Clostridia bacteria as part of a UK collaboration developing aimed at developing microbiome targeted therapeutics.
‘Splinter-like’ nanostructures have been developed by researchers in the US to deliver biomolecules straight into patient cells for immune-oncology and gene therapies.
A new method to predict the physical stability of drug candidates is attracting interest from pharmaceutical companies who could use the technology to de-risk early development.
Takeda Pharmaceuticals will work with Wave Life Sciences to develop nucleic acid therapies for central nervous system disorders, including Huntington’s and Lou Gehrig’s disease.
AMAG has received approval for its preterm birth risk reduction product combining the drug product supplied by Pfizer and Antares Pharma’s auto-injection system.
The Republic of Ireland will move its population from short-acting to extended half-life haemophilia therapies, under an exclusive two-year deal with Sobi.
A patient-controlled injector and a prefilled pen for patients with hand dexterity issues were among the drug delivery technologies celebrated at PharmaPack Europe’s awards this year.
Vical has dismissed 40 employees and abandoned a Phase III vaccine candidate in a reshuffle it says allows for greater resources on HSV-2 and antifungal trials.
